Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact
By
Ellen Licking (Contributor), Jessica Merrill / Email the Authors / START-UP May 2010, Vol. 15, No. 5
Venture Round / Word Count: 1139 / Article # 2010900124
Executive Summary
The April 15 deal between Agios Pharmaceuticals Inc., a start-up barely two years old working in a novel area of cancer research, and Celgene Corp. is noteworthy for a number of reasons, among them its sheer size: the $130 million up-front payment associated with the deal is the largest year-to-date for a pharmaceutical alliance for which metrics have been disclosed, and is particularly
hefty for a start-up that has yet to put a molecule in the clinic.
$50.00
Buy Now
For $50.00, purchase this 1139-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.